Potential drug target for Zika, similar viruses identified

Image
IANS New York
Last Updated : Jun 18 2016 | 3:42 PM IST

Scientists have identified a single gene pathway that can disrupt Zika and similar viruses from spreading in the body and also act as a potential drug target for such deadly diseases.

The findings showed that disabling SPCS1 -- in both human and insect cells -- reduces viral infection and does not negatively affect the cells themselves.

"We wanted to find out if we could identify genes present in the host cells that are absolutely required by the virus for infection," said Michael Diamond, Professor at Washington University.

While the absence of SPCS1 gene shut down the spread of flaviviruses, eliminating the gene had no detrimental effect on other types of viruses, including alphaviruses, bunyaviruses and rhabdoviruses, the researchers said.

"In these viruses, without SPCS1 gene the chain reaction doesn't happen and the virus can't spread. So this gene can act as a potential drug target because it disrupts the virus but not the host," Diamond added.

Viruses hijack host cells to replicate and spread, making them dependent upon the genetic material of the organisms they infect.

If a cell lacks a gene that the virus requires for infection, the virus will have to stop in its tracks and will enable the cells to survive. Thus the missing gene becomes vital to spread of the virus.

"Flaviviruses appear to be uniquely dependent particularly on SPCS1 gene to release the viral particle," Diamond noted.

For the study, published in the journal Nature, the team first conducted experiments on West Nile virus and then found that the same results held true for other Flaviviridae family members, including Zika, dengue, yellow fever, Japanese encephalitis and hepatitis C viruses.

Using gene-editing technology called CRISPR that is capable of selectively shutting down individual genes, the researchers identified only nine key genes that the virus relies on for infection or to spread.

--IANS

rt/ask/vm

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jun 18 2016 | 3:32 PM IST

Next Story